Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06907862

The SWITCH (Substitution of High With Low Ultra-processed Soy Protein Foods In a Guideline-based Diet inTervention for Cardiometabolic Health) Trial

This is a randomized, controlled, parallel study with 3 experimental arms aimed to assess the effect of a digital dietary intervention (web-based app, online behavior change curriculum) enhanced with 10 servings of vegetables and fruit (5 as dietary advice within the app, 5 within a dehydrated vegetable and fruit blend), with or without high Ultra Processed Food (UPF) soy-containing proteins compared to standard of care (usual care) on systolic blood pressure (SBP; primary outcome), and other key cardiometabolic endpoints over 12-weeks in adults living with hypertension and obesity, 50% with type 2 diabetes. The main questions this study aims to answer are:

1. Are nutrient-dense, high-UPF soy-protein foods similar (non-inferior) to low-UPF soy-protein foods in the context of a guidelines-based diet in their effect on blood pressure and other cardiometabolic risk factors? 2. Does an enhanced digital dietary intervention lead to meaningful reductions in blood pressure and other cardiometabolic risk factors compared to standard of care?

Participants who are eligible and consent to be part of this study will be randomized to one of the following groups: 1) Active treatment (high-UPF soy-containing enhanced digital dietary intervention), 2) Reference treatment (low-UPF soy-containing enhanced digital dietary intervention), or 3) Control (standard of care).

Participant Requirements:

During the 12-week intervention, all participants will be required to attend in-person clinic visits at baseline (week 0), week 8 and 12.

Baseline Visit (Week 0): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).

* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse). * Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit. * Bring fecal and urine samples from home. * Complete and review all questionnaires received via email one week prior.

Telephone Check-in (Week 1):

One week after beginning the study, the study staff will call participants to check in on how participants are following the protocol and answer any questions.

Mid-Study Visit (Week 8): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).

* Have their office blood pressure and anthropometric measurements taken. * Complete and review all questionnaires received via email one week prior * Review the 3-day food records completed using the Keenoa mobile app one week prior to clinic visit.

Final Study Visit (Week 12): Participants will be asked to arrive in a fasted state (no food or beverages, except water, for 10-12 hours before the visit).

* Undergo various assessments, including anthropometric measurements, office blood pressure readings, and blood sampling (via a capillary finger prick and blood sample taken by the study nurse). * Review the 7-day food records completed using the Keenoa mobile app one week prior to clinic visit. * Bring fecal and urine samples from home. * Complete and review all questionnaires received via email one week prior.

Throughout the study, participants will be asked to continue their usual lifestyle and physical activity.

Additional Requirements for Treatment Groups:

Participants randomized to the active and reference treatment groups will also be required to:

* Incorporate a study vegetable and fruit blend (provided) into their daily diet for the full 12 weeks * Consume soy products categorized as either high ultra processed soy foods at least 4 servings per day, including at least 2 servings of ultra processed soy milk and 2 servings of other soy-based products (e.g., soy yogurt, soy burgers, or soy ground round) or non-ultra processed soy foods at least 4 servings per day, including at least 2 servings of minimally processed soy milk, 1 serving of edamame or roasted soy nuts, and 1 serving of tofu or tempeh * Participate in the digital dietary intervention, which includes: a health app, 7-day Kickstart Package, weekly text message support, and a 7-session online interactive program designed based on behaviour change theory * Attend a virtual focus group at Week 4 and complete an online feedback questionnaire

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Obesity (BMI and waist circumference using sex and ethnic-specific thresholds for obesity and significant abdominal adiposity)
  • adults (≥18years)
  • hypertension (SBP 120-160 mmHg)
  • on stable antihypertensive, antihyperglycemic, antihyperlipidemic, or anti-obesity medications (≥3-months)
  • not planning new weight loss for the duration of the trial
  • 50% living with type 2 diabetes, HbA1c 6.5-9.0%

Exclusion criteria

  • Individuals with a history of major cardiovascular events in the last year (stroke or myocardial infarction)
  • type 1 diabetes diagnosis
  • recent weight loss or weight gain (≥5% over <6 months)
  • current treatment with insulin
  • eating disorders; substance abuse disorders
  • serious depression or psychiatric disorders
  • bariatric or recent surgery (<6 months)
  • uncontrolled hypertension (SBP/DBP >160/100 mmHg)
  • angina pectoris
  • gastrointestinal and malabsorption disorders (i.e. inflammatory bowel disease, celiac), pancreatitis, chronic kidney or liver disease, cardiac condition that compromises normal function (e.g. mitral valve disease, heart failure), major disability or disorder requiring continuous medical attention.
  • herb or supplement use that may affect primary outcome.
  • alcohol use >3 drinks/day; participation in another trial.
  • allergies/intolerances to soy; allergies/intolerances to tree nuts, peanuts and seeds (the combination of all 3).
  • chronic or prescribed use of certain medications including prescription high dose NSAIDs, antacids, warfarin, medications affecting NO synthesis (i.e. sildenafil, organic nitrates, etc.)
  • acute or chronic infection (e.g. active HIV, TB, COVID-19, chronic inflammatory infections)
  • chronic inflammatory condition (such as rheumatoid arthritis)
  • use of antibiotics within 3-months of the study start

Treatment and study plan

Reference Treatment

Other

≥4 servings/day of soy products categorized as non-ultra processed according to the NOVA classification system (NOVA non-Group 4): ≥2 servings/day of a Group 1 soy milk and ≥1 serving/day of another Group 1 food, such as edamame or roasted soy nuts, and ≥1 serving/day of a Group 3 food, such as tofu or tempeh) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)

Control

Other

Usual care provided by their primary care physician and/or specialist.

Active Treatment

Other

≥4 servings/day of soy products categorized as ultra processed according to the NOVA classification system (NOVA Group 4): ≥2 servings/day of soy milk and ≥2 servings/day of other soy-based products such as soy yogurt, soy burgers, or soy ground round) as part of a digital dietary intervention, enhanced with 10 servings of vegetables and fruit (5 as dietary advice and 5 provided in a blend of dehydrated vegetables and fruit)

Primary outcomes

  1. Systolic Blood Pressure

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline.

Secondary outcomes

  1. Key Secondary Outcome: non-high-density lipoprotein cholesterol [non-HDL-C]

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline.

  2. Body weight

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline.

  3. Diastolic Blood Pressure

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline.

  4. Blood Pressure Targets

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in proportion achieving therapeutic targets for blood pressure (SBP<140mmHg and DBP <90mmHg for those without diabetes; SBP <130mmHg and DBP <80mmHg for those with diabetes; SBP <120mmHg for Hypertension Canada high-risk patients)

  5. Blood Lipids

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in low-density lipoprotein-cholesterol (LDL-C), triglycerides, and high-density lipoprotein-cholesterol (HDL-C) from baseline.

  6. Blood Lipid Targets

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in proportion achieving therapeutic targets for lipids (non-HDL-C <2.6mmol/L, LDL-C <2.0mmol/L)

  7. Glycemic control

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in HbA1c from baseline.

  8. Glycemic control

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in fasting glucose from baseline.

  9. Insulin

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in fasting insulin from baseline.

  10. Insulin Resistance

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in insulin resistance (HOMA-IR) from baseline.

  11. Inflammation

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in C-Reactive Protein (CRP) from baseline.

  12. Body Composition

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in body mass index from baseline.

  13. Body Composition

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in waist circumference from baseline.

  14. Body Composition

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change in body fat from baseline.

Other outcomes

  1. Exploratory mechanistic endpoint - DNA Methylation

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline in DNA methylation.

  2. Exploratory mechanistic endpoint - Telomere Length

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline in telomere length.

  3. Exploratory mechanistic endpoint - Intestinal Permeability

    Time frame: from enrollment to the end of treatment at 12 weeks

    Difference in mean change from baseline in intestinal permeability.

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Chiavaroli, PhD

CONTACT

[email protected]

416-946-0579

Sponsors and collaborators

Lead sponsor

University of Toronto

Other

Registry information

Acronym: SWITCH

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Apr 2, 2025
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.